Two independent studies applied CRISPR-based genetic editing – one to treat leukemia and the other to target myeloma – to overcome the challenges faced by CAR T cells, such as exhaustion, impaired activation and fratricide, a phenomenon in which they attack each other. Read More
Tevard Biosciences Inc. has presented new preclinical data on the use of therapeutic suppressor tRNAs (suptRNAs) for the treatment of Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy (DCM). The data show potent restoration of full-length functional proteins in models of DMD and DCM caused by titin truncations (DCM-TTNtv). Read More
Orexo AB’s subsidiary Orexo US Inc. has been awarded $8 million in funding by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of OX-390, an intranasal rescue medication for adulterated opioid overdoses. Read More
Climb Bio Inc. has announced results from a completed nonhuman primate (NHP) study of CLYM-116, an anti-APRIL monoclonal antibody (mAb) in development for IgA nephropathy. Read More
Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more. Read More
Biolinerx Ltd. and Hemispherian AS have established a joint venture (JV) to develop GLIX-1, Hemispherian’s lead drug candidate being developed as a potential treatment for newly diagnosed and recurrent glioblastoma. Read More
Chineses researchers investigated the relationship between formyl peptide receptor 1 (FPR1) expression and neurodegeneration in multiple sclerosis (MS), specifically evaluating the therapeutic potential of the FPR1 antagonist T-0080. Read More
Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer. Read More
In heart failure, the heart does not oxygenate body tissues adequately. A standard treatment is SGLT2 inhibitors such as empagliflozin and dapagliflozin, derived from the national product phlorizin. However, long-term use of these inhibitors increases risk of renal damage and euglycemic diabetic ketoacidosis. Read More
Jiangsu Synthgene Biotechnology Co. Ltd. has synthesized platinum complexes acting as radiosensitizers reported to be useful for the treatment of cancer. Read More
Antengene Corp. Ltd. and Antengene Discovery Ltd. have divulged phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors acting as ferroptosis inducers reported to be useful for the treatment of cancer. Read More
Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a modulator of IL-1 receptor and Toll-like receptor (TLR) signaling and has emerged as a promising therapeutic target for several inflammatory diseases. Gilead Sciences Inc. and Nurix Therapeutics Inc. recently presented data generated in a preclinical murine model of AD with their IRAK-4 degrader GS-6791. Read More
